Ustekinumab biosimilar(Formycon)

乌司奴单抗生物类似药（Formycon）

Report date: 2026/05/26 20:00:28

Base Information

Drug NameUstekinumab biosimilar(Formycon)
Drug Alias NameUstekinumab-AAUZOTULFIFymskinaFYB-202
ClassificationBiologics > BiosimilarBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody human
Mechanisms of ActionInterleukin-12 inhibitorsInterleukin-23 inhibitors
TargetsInterleukin-12Interleukin-23
Therapy Area/IndicationsPlaque psoriasisPsoriasisCrohn Disease +[5] 
Global Approved IndicationsPsoriasisCrohn DiseaseColitis, Ulcerative +[4] 
Approved Indications in ChinaN/A
Original Approved Country/TerritoryEU
Original Approved Date2024/09/25
Country/TerritoryUnited StatesUkrainePoland +[6] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaN/A
Originator CompaniesFormycon AG
China Registration ClassN/A

Develop Information

Active CompaniesFormycon AGFresenius Kabi Usa LlcBioeq Gmbh +[4] 
Inactive CompaniesN/A
Active IndicationsPlaque psoriasisPsoriasisCrohn Disease +[5] 
Inactive IndicationsN/A

Other Information

ATC CodeL04AC05
Related LinksN/A